This trial is testing whether niraparib, which blocks the PARP enzyme, can shrink tumors in patients with leiomyosarcoma.
1 Primary · 4 Secondary · Reporting Duration: Up to 2 years after study treatment
Experimental Treatment
22 Total Participants · 1 Treatment Group
Primary Treatment: Niraparib Tosylate Monohydrate · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Ohio | 100.0% |
18 - 65 | 100.0% |
Ohio State University Comprehensive Cancer Center | 100.0% |
Met criteria | 100.0% |